Work

#124 - Quantifying Placebo Response in Cholestatic Pruritus Trials: a Systematic Review and Meta-analysis

Year: 2026
Type: article
Abstract: Introduction and Objectives Cholestatic pruritus is a burdensome manifestation of cholestatic liver diseases and has become a key patient-centered endpoint in therapeutic trials. However, its subjective and variable nature makes trial outcomes particularly susceptible to placebo-effects. We sought to estimate the magnitude of placebo response and identify potential trial-level factors associated with placebo-related improvement in contemporary trials of cholestatic pruritus. Materials and Methods We conducted a systematic review and meta-analysis of placebo-controlled-randomized trials assessing ileal-bile-acid-transporter inhibitors or peroxisome-proliferator-activated-receptor agonists in cholestatic pruritus. PubMed, Embase, and CENTRAL were searched through March/2026. Primary outcomes were placebo responder rate and absolute change in pruritus intensity on a 0–10 scale. Random-effects models used restricted-maximum likelihood with Hartung–Knapp adjustment. Potential moderators were assessed using mixed-effects meta-regression. Results Thirteen trials comprising 548 placebo-treated participants were included. Across placebo arms, pruritus intensity significantly improved, with a pooled mean reduction of 1.53 points on a 0–10 scale. In moderate-to-severe pruritus trials, the pooled placebo-responder rate was 27.4% (95%CI, 17.9%–39.5%). Improvement was consistent across age groups. Among patients with primary biliary cholangitis, placebo was associated with a significant reduction in the PBC-40-itch-domain score, with a mean decrease of 9.13 points, whereas improvement in the 5-D-Itch-Scale was not significant. Higher baseline total bilirubin was associated with smaller placebo-related reductions in pruritus intensity. Conclusions Placebo response is clinically meaningful and varies according to the endpoint used in cholestatic pruritus trials. These findings provide quantitative benchmarks to guide endpoint selection, trial design, and sample-size estimation in future studies evaluating antipruritic therapies.
Language: English
Open Access status: gold
Estimated APC paid: $1,500
OpenAlex ID: W7204264108
FWCI:
Cites:
Cited by:
Related to: 10